GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 2 YEARS OF DISCOVER-2

被引：0
|
作者：
Curtis, J. [1 ]
Mcinnes, I. [2 ]
Rahman, P. [3 ]
Gladman, D. D. [4 ,5 ]
Yang, F. [6 ]
Peterson, S. [6 ]
Kollmeier, A. [7 ]
Shiff, N. [6 ,8 ]
Han, C. [9 ]
Shawi, M. [10 ]
Tillett, W. [11 ]
Mease, P. J. [12 ,13 ]
机构：
[1] Univ Alabama Birmingham, Dept Med Immunol & Rheumatol, Birmingham, AL USA
[2] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[3] Mem Univ Newfoundland, Craig L Dobbin Genet Res Ctr, St John, NF, Canada
[4] Toronto Western Hosp, Schroeder Atrhiritis Inst, Dept Med, Ctr Prognosis Studies Rheumat Dis, Toronto, ON, Canada
[5] Krebmil, Res Inst, Toronto, ON, Canada
[6] Janssen Global Serv LLC, Immunol, Horsham, PA USA
[7] Janssen Res & Dev LLC, Immunol, San Diego, CA USA
[8] Univ Saskatchewan, Dept Community Hlth & Epidemiol, Coll Med, Saskatoon, SK, Canada
[9] Janssen Res & Dev LLC, Immunol, Spring House, PA USA
[10] Janssen Pharmaceut Companies Johnson Johnson, Immunol Global Med Affairs, Horsham, PA USA
[11] Royal Natl Hosp Rheumat Dis, Dept Pharm Pharmacol, Ctr Therapeut Innovat, Bath, Avon, England
[12] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[13] Univ Washington, Dept Rheumatol Res, Sch Med, Seattle, WA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1366
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0888
引用
收藏
页码：1568 / 1569
页数：2
相关论文
共 50 条
  • [31] The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Jeffrey R. Curtis
    Iain B. McInnes
    Proton Rahman
    Dafna D. Gladman
    Feifei Yang
    Steven Peterson
    Prasheen Agarwal
    Alexa P. Kollmeier
    Elizabeth C. Hsia
    Chenglong Han
    Natalie J. Shiff
    May Shawi
    William Tillett
    Philip J. Mease
    Advances in Therapy, 2022, 39 : 4632 - 4644
  • [32] Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
    Coates, Laura C.
    Ritchlin, Christopher T.
    Gossec, Laure
    Helliwell, Philip S.
    Rahman, Proton
    Kollmeier, Alexa P.
    Xu, Xie L.
    Shawi, May
    Karyekar, Chetan S.
    Contre, Christine
    Noel, Wim
    Sheng, Shihong
    Wang, Yanli
    Xu, Stephen
    Mease, Philip J.
    RHEUMATOLOGY, 2023, 62 (02) : 606 - 616
  • [33] A NOVEL PSORIATIC ARTHRITIS COMPOSITE ENDPOINT COMBINING TREATMENT TARGETS FOR SKIN AND JOINTS: POOLED RESULTS FROM THE GUSELKUMAB DISCOVER-1 AND DISCOVER-2 STUDIES
    Boehncke, W. H.
    Gottlieb, A. B.
    Soriano, E.
    Ogdie, A.
    Ziouzina, O.
    Rampakakis, E.
    Xu, X. L.
    Chakravarty, S. D.
    Shawi, M.
    Marrache, M.
    Kollmeier, A.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 261 - 262
  • [34] GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Ranza, Roberto
    Coates, Laura C.
    Ritchlirn, Christopher T.
    Gossec, Laure
    Helliwell, Philip S.
    Rahman, Proton
    Hsia, Elizabeth C.
    Kollmeier, Alexa P.
    Xu, Xie L.
    Karyekar, Chetan S.
    Shawi, May
    Noel, Wim
    Jiang, Yusang
    Sheng, Shihong
    Wang, Yanli
    Mease, Philip J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S101 - S101
  • [35] GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY
    Rahman, P.
    Mcinnes, I.
    Deodhar, A.
    Schett, G.
    Mease, P. J.
    Shawi, M.
    Cua, D.
    Sherlock, J.
    Kollmeier, A.
    Xu, X. L.
    Jiang, Y.
    Sheng, S.
    Ritchlin, C. T.
    Mcgonagle, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 826 - 827
  • [36] GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Coates, L. C.
    Ritchlin, C. T.
    Gossec, L.
    Helliwell, P.
    Rahman, P.
    Hsia, E. C.
    Kollmeier, A.
    Xu, X. L.
    Karyekar, C.
    Shawi, M.
    Noel, W.
    Jiang, Y.
    Sheng, S.
    Wang, Y.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 781 - 782
  • [37] Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
    Coates, Laura
    Ritchlin, Christopher
    Gossec, Laure
    Helliwell, Philip S.
    Rahman, Proton
    Hsia, Elizabeth
    Kollmeier, Alexa
    Xu, Xie
    Karyekar, Chetan
    Shawi, May
    Noel, Wim
    Jiang, Yusang
    Sheng, Shihong
    Wang, Yanli
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2774 - 2776
  • [38] Impact of guselkumab on fatigue and mediation analysis of independent treatment effect of guselkumab on fatigue in patients with active psoriatic arthritis: Results from DISCOVER-1&2
    Rahman, Proton
    Helliwell, Philip S.
    Deodhar, Atul
    Kollmeier, Alexa P.
    Hsia, Elizabeth
    Zhou, Bei
    Lin, Xiwu
    Han, Chenglong
    Yang, Ya-Wen
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB153 - AB153
  • [39] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial (vol 395, pg 1126, 2020)
    Mease, P. J.
    Rahman, P.
    Gottlieb, A. B.
    LANCET, 2020, 395 (10230): : 1114 - 1114
  • [40] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Tahir, Hasan
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pascale, Pellet
    Delicha, Evie Maria
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345